Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

This study is investigating a new medicine called Vonicog Alfa for children with severe Von Willebrand Disease (VWD). VWD is a condition that affects how your blood clots. The main goal is to see how well Vonicog Alfa prevents bleeding when given regularly. This is for children who have already been treated with other VWD medicines. Participants will take Vonicog Alfa for a year and visit the clinic five times during that period. This study aims to find a potentially better way to manage bleeding for children living with this condition.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Takeda
Einschreibeziel
24
Starten
06 Nov 2024
Geschätzte Fertigstellung
11 Apr 2030

Worum geht es in dieser Studie?

This study is designed to learn more about a new medicine called Vonicog Alfa. It's for children who have a serious blood condition called Von Willebrand Disease (VWD). People with VWD have trouble with their blood clotting properly, which can lead to bleeding problems.

The main purpose of this study is to see if Vonicog Alfa can help prevent bleeding episodes in children. This type of treatment, where medicine is given regularly to prevent problems, is called prophylaxis. The study is particularly interested in children who have already been using other medicines for their VWD, either to stop bleeding when it happens or as a regular preventative treatment.

By taking part, children will receive Vonicog Alfa for 12 months. Researchers will then carefully check how effective it is at reducing bleeding events. This research is important because it could lead to new or improved ways to help children manage their VWD and live healthier lives.

Wichtige Erkenntnisse

  • This study is testing a new medicine, Vonicog Alfa, for severe Von Willebrand Disease.
  • It aims to see if the medicine can prevent bleeding in children.
  • Children aged under 18 who have used other VWD treatments are eligible.
  • Participants will receive the medicine for one year.
  • There will be 5 clinic visits over the year to check on progress.

Wer könnte berechtigt sein?

To be considered for this study, children need to have a confirmed diagnosis of severe Von Willebrand Disease. This means their blood clotting factor levels are quite low, and they've needed treatment for bleeding in the past. We're looking for children who are under 18 years old.

Also, a child must have received other Von Willebrand Factor (VWF) treatments previously. This could be either regular treatment to prevent bleeding for at least 12 months (or 6 months if under 2 years old) or treatment given only when bleeding happened, for at least 12 months (or 6 months if under 2 years old).

Finally, for older children (2 years and above), we need to be able to look at their medical records for the past year to understand their bleeding history and how it was treated. For those under 2 years old, we'll need similar records from the past 6 months.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Does your child have a diagnosis of severe Von Willebrand Disease?
  2. Ist Ihr Kind unter 18 Jahre alt?
  3. Has your child been treated for Von Willebrand Disease before?
  4. Do you have good records of your child's bleeding history for the past 6-12 months?
  5. Has a doctor recommended preventative treatment for your child's VWD?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If your child takes part in this study, they will receive the study medicine, Vonicog Alfa, for 12 months. After they start the treatment, they will need to visit the study clinic five times over that year for checks. These visits will help the doctors see how your child is doing and how the medicine is working. The total study duration for each child will be 12 months for receiving the medicine, plus the time for these clinic visits.

Potenzielle Risiken und Vorteile

Taking part in any study has potential benefits and risks. The potential benefits of this study include receiving a new medicine that might be more effective at preventing bleeding episodes for your child. However, like all medicines, Vonicog Alfa might have side effects, and some benefits might not happen for all participants. Your child also has the right to leave the study at any time, for any reason, without it affecting their usual medical care.

Standorte (23)

  • Universität von Alabama in Birmingham
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten· Rekrutierung
  • Arnold Palmer Childrens Hosptial
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten· Noch nicht rekrutiert
  • Bleeding and Clotting Disorders Institute
    Verifizierte Postleitzahl
    Peoria, United States· Rekrutierung
  • Riley Hospital for Children Indiana University Health
    Verifizierte Postleitzahl
    Indianapolis, Vereinigte Staaten· Rekrutierung
  • University of Iowa Hospitals & Clinics PARENT
    Verifizierte Postleitzahl
    Iowa City, Vereinigte Staaten· Rekrutierung
  • Childrens Hospital of Michigan
    Verifizierte Postleitzahl
    Detroit, Vereinigte Staaten· Rekrutierung
  • Michigan State University Center for Bleeding Disorders & Clotting Disorders
    Verifizierte Postleitzahl
    East Lansing, Vereinigte Staaten· Noch nicht rekrutiert
  • Children's Health Care d/b/a Children's Minnesota
    Verifizierte Postleitzahl
    Minneapolis, Vereinigte Staaten· Rekrutierung
  • Cure 4 the Kids
    Verifizierte Postleitzahl
    Las Vegas, Vereinigte Staaten· Rekrutierung
  • Rutgers - Robert Wood Johnson Medical School
    Verifizierte Postleitzahl
    New Brunswick, United States· Rekrutierung
  • New York - Presbyterian/Weill Cornell Medical Center
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten· Rekrutierung
  • Medical University of South Carolina (MUSC)
    Verifizierte Postleitzahl
    Charleston, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is Von Willebrand Disease?

It's a condition where your blood doesn't clot properly, which can lead to bleeding problems.

What is Vonicog Alfa?

It's a new medicine being studied to help prevent bleeding in children with Von Willebrand Disease.

How long will my child take part in the study?

Your child will receive the study medicine for 12 months and have 5 clinic visits during that time.

Will my child stop their current VWD medicine?

The study is for children who have used VWD medicines before, and the doctor will discuss whether switching to Vonicog Alfa is suitable.

Are there any age limits for this study?

Yes, children under 18 years old can take part.

Wie Sie mehr erfahren können

Takeda Contact

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study of Vonicog Alfa (rVWF) in Children With Severe Von W… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.